Heart drug mavacamten shows Real-World promise in canada
NCT ID NCT06338202
First seen Dec 10, 2025 · Last updated May 15, 2026 · Updated 23 times
Summary
This study reviewed medical charts of 115 Canadian adults with obstructive hypertrophic cardiomyopathy (oHCM) who started taking mavacamten. Researchers wanted to see how the drug improved symptoms and heart function in routine care. The study found that many patients had better heart function and fewer symptoms after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
London Health Science Centre (LHSC)
London, Ontario, N6A 5A5, Canada
Conditions
Explore the condition pages connected to this study.